Small Interfering RNA (siRNA) Therapeutics Market Size $2.55B In 2024, Forecast To $12.38B By 2033 At 17.4% CAGR

Small Interfering RNA (siRNA) therapeutics Market reached US$ 2.55 billion in 2024 and is expected to reach US$ 12.38 billion by 2033, growing at a CAGR of 17.4% during the forecast period 2025-2033.

The Small Interfering RNA (siRNA) Therapeutics Market report, released by DataM Intelligence, offers comprehensive insights and thorough analysis of major market trends, growth prospects, and emerging challenges. With a strong focus on actionable intelligence, DataM Intelligence equips businesses with the knowledge needed to make strategic decisions and maintain a competitive advantage. Utilizing a blend of qualitative and quantitative research methodologies, the firm delivers in-depth reports that support clients in understanding complex market dynamics, fostering strategic development, and capturing new opportunities in today's rapidly changing global environment.

Request a Premium Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/small-interfering-rna-therapeutics-market?kb

Evolving Market Forces and Opportunities:

Small Interfering RNA (siRNA) therapeutics use short, double-stranded RNA molecules to specifically silence disease-causing genes. This innovative approach holds promise for treating a range of genetic and viral diseases by targeting mRNA degradation.

Key Industry Players Driving the Small Interfering RNA (siRNA) Therapeutics Market:

Alnylam Pharmaceuticals, Inc., Novartis AG, and Novo Nordisk A/S., among others.

Small Interfering RNA (siRNA) Therapeutics Market Emerging Players

The emerging players in the small interfering RNA (siRNA) therapeutics market are Arbutus Biopharma, ADARx Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., and Amgen Inc., among others.

Industry Development:

In April 2025, Alnylam Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the approval of vutrisiran for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.

In March 2025, the U.S. Food and Drug Administration (FDA) approved fitusiran (Qfitlia), the seventh siRNA therapy developed by Alnylam Pharmaceuticals, Inc., for treating Hemophilia A and B. This approval marks fitusiran as the first siRNA therapy authorized for hemophilia, functioning by reducing antithrombin (AT), a protein that limits blood clotting.

Research Methodology:

Both primary and secondary data sources have been used in the global Small Interfering RNA (siRNA) Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/small-interfering-rna-therapeutics-market?kb

Segment Covered in the Small Interfering RNA (siRNA) Therapeutics Market:

By Drug: Patisiran, Givosiran, Lumasiran, Inclisiran, Nedosiran, Vutrisiran, Others

By Indication: Transthyretin Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Primary Hyperlipidemia, Others

By Route of Administration: Intravenous, Subcutaneous

Regional Overview for Small Interfering RNA (siRNA) Therapeutics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/small-interfering-rna-therapeutics-market?kb

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Small Interfering RNA (siRNA) Therapeutics market?

➠ Who are the leading manufacturers in the global Small Interfering RNA (siRNA) Therapeutics industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Small Interfering RNA (siRNA) Therapeutics industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Small Interfering RNA (siRNA) Therapeutics market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.